Clinical trials: Women With Breast Cancer
Postmenopausal Women, Locally Advanced Metastatic Breast Cancer
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
This was a multi-center, Israeli phase II open label study evaluating treatment with RAD001 (10 mg daily) combined with letrozole (2.5 mg daily) in postmenopausal women after recurrence or progression on Tamoxifen, Anastrozole or…
- Conditions
- Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT01231659
- Testing
- Everolimus, Letrozole
- Where
- 7 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Ovarian Cancer
Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer.
The choice of treatments for cancers by systemic way - chemotherapy, hormone therapy and targeted therapies - is currently defined by criteria for population groups and not to an individual.
- Trial name
- ONCO S-O (NCT02910622)
- Testing
- Chimio-oncogramme
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Limoges
Breast Cancer
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay
The primary objective of this study is to assess the extent to which the Prosigna™ Breast Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and…
- Trial name
- NCT01899079
- Where
- 7 sites in Spain
- Volunteers
- 217 people
- Sponsor
- NanoString Technologies, Inc.
Breast Cancer, Cervix Cancer
Carboplatin-cyclophosphamide Combined With Atezolizumab
This is a single centre, 3+3, dose finding, open label, phase 1b clinical study of carboplatin and cyclophosphamide, in combination with atezolizumab.
- Conditions
- Breast Cancer, Cervix Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- PROLOG (NCT02914470)
- Testing
- carbplatin, cyclophophamide, atezolizumab
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Breast Cancer
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
We are trying to develop better ways to detect when cancer therapies are working.
- Trial name
- NCT00156273
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II
Effect of Hemp-CBD on Patients With CIPN
The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy (CIPN) among non-metastatic breast…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer
- Trial name
- Coala-T-CBD (NCT04398446)
- Testing
- Hemp-based CBD
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Main Line Health
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Breast Cancer
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00934895
- Testing
- everolimus, abraxane
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004175
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Northwestern University
Breast Cancer
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel followed by surgery in…
- Trial name
- NCT00003953
- Testing
- filgrastim, CMF regimen, docetaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Ovarian Cancer
Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers
This study will measure the efficacy of scalp cooling with the Paxman Scalp Cooling (PSC) device in a diverse patient population with success measured as prevention of more than 50% hair loss during chemotherapy.
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecologic Neoplasm, Endometrial Cancer
- Trial name
- NCT04626895
- Testing
- Paxman Scalp Cooling Device
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Medstar Health Research Institute
Gastric Cancer, Invasive Breast Cancer
CONFIRM: Magnetic Resonance Guided Radiation Therapy
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer.
- Conditions
- Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma
- Trial name
- CONFIRM (NCT04368702)
- Testing
- Viewray MRIdian® Linac
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer
Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer
RATIONALE: Removing axillary lymph nodes may be effective in stopping the spread of breast cancer cells. It is not yet known if surgery to remove breast cancer is more effective with or without lymph node removal.
- Trial name
- 10-93 (NCT00002528)
- Testing
- tamoxifen citrate, conventional surgery, radiation therapy
- Where
- 21 sites in Australia, Hungary and 7 more
- Volunteers
- 473 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
Hypothesis: A higher sensitivity to breast cancer detection can be achieved in women with dense breast tissue by performing and reviewing results of Automated Breast Ultrasound (ABUS) and Digital X-Ray Mammography (XRM) together…
- Trial name
- somo•InSIGHT (NCT00816530)
- Testing
- Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
- Where
- 11 sites in United States
- Volunteers
- 15,679 people
- Sponsor
- U-Systems, Inc.
Breast Cancer, Ovarian Cancer
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Open-label, cohort study to determine the feasibility and tolerability of the combination of daily niraparib and daily or thrice weekly everolimus for one 28-day cycle in patients with advanced ovarian and breast cancer.
- Trial name
- NCT03154281
- Testing
- niraparib, everolimus
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Ovarian Cancer, Triple-negative Breast Cancer
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in…
- Conditions
- Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
- Trial name
- NCT03992131
- Testing
- Rucaparib, Lucitanib, Sacituzumab govitecan
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- pharmaand GmbH
Breast Cancer
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and cyclophosphamide, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00074139
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Breast Cancer, Stage 0 Breast Cancer
A Study of Revaree Plus in People With Breast Cancer
The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.
- Conditions
- Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT07042581
- Testing
- Revaree Plus
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Health Behavior, Breast Cancer Screening
Improving Breast Cancer Screening Uptake Through Tailored Reminder Letters
The goal of this trial is to learn whether a culturally and linguistically tailored reminder letter can increase participation in the Flemish Breast Cancer Screening Program among women who previously did not attend screening.
- Conditions
- Health Behavior, Breast Cancer Screening, Mammography
- Trial name
- ENTER (NCT07472036)
- Testing
- Tailored reminder letter
- Where
- 2 sites in Belgium
- Volunteers
- 7,947 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.